Open AccessT023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
Publication year - 2018
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000547935.17200.58
Subject(s) - brentuximab vedotin , regimen , medicine , vincristine , oncology , hodgkin lymphoma , lymphoma , chemotherapy , cyclophosphamide